Literature DB >> 29584578

Longitudinal Associations of Metabolic Syndrome Severity Between Childhood and Young Adulthood: The Bogalusa Heart Study.

Linda X Wang1, Stephanie L Filipp2, Elaine M Urbina3, Matthew J Gurka2, Mark D DeBoer1.   

Abstract

BACKGROUND: Childhood metabolic syndrome (MetS) is associated with insulin resistance and increased risk for later development of type 2 diabetes (T2DM) and cardiovascular disease (CVD). In using MetS severity z-scores, our objective was to assess longitudinal associations in MetS severity, fasting insulin levels as a sign of insulin resistance and risk for T2DM, and uric acid levels as a biomarker of oxidative stress leading to CVD.
METHODS: We used linear regression to analyze longitudinal data from 285 white and black participants from the Bogalusa Heart Study evaluated at baseline at ages 5-19 and as young adults after a mean of 12.0 years follow-up. We assessed correlations between childhood MetS severity and young-adult MetS severity, fasting insulin, and uric acid levels, both overall and by sex- and racial subgroups.
RESULTS: Overall, childhood MetS z-scores were positively associated with young-adult MetS z-scores (r = 0.52), insulin (r = 0.34), and uric acid (r = 0.28) (all P < 0.001). These associations were consistent across all sex- and racial subgroups, except for young adult uric acid in white males in which childhood MetS-z was not associated (r = 0.15, P = 0.243). There was a strong cross-sectional association of young-adult MetS z-scores with insulin (r = 0.70) and uric acid (r = 0.57) (both P < 0.001), which was consistent for all sex- and racial subgroups.
CONCLUSIONS: These positive longitudinal correlations between childhood MetS z-scores and markers of later insulin resistance and oxidative stress suggest long-term durability of risk for CVD and T2DM. This suggests potential for MetS severity to serve as an indicator to monitor for future risk of T2DM and CVD.

Entities:  

Keywords:  cardiovascular disease; insulin resistance; metabolic syndrome; oxidative stress; risk; type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29584578      PMCID: PMC5984565          DOI: 10.1089/met.2017.0160

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  32 in total

Review 1.  The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences.

Authors:  Sarah de Ferranti; Dariush Mozaffarian
Journal:  Clin Chem       Date:  2008-04-24       Impact factor: 8.327

Review 2.  Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions.

Authors:  Mark D DeBoer
Journal:  Nutrition       Date:  2012-09-28       Impact factor: 4.008

3.  Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study.

Authors:  W Bao; S R Srinivasan; W A Wattigney; G S Berenson
Journal:  Arch Intern Med       Date:  1994-08-22

Review 4.  The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.

Authors:  Salvatore Mottillo; Kristian B Filion; Jacques Genest; Lawrence Joseph; Louise Pilote; Paul Poirier; Stéphane Rinfret; Ernesto L Schiffrin; Mark J Eisenberg
Journal:  J Am Coll Cardiol       Date:  2010-09-28       Impact factor: 24.094

5.  Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents.

Authors:  Earl S Ford; Chaoyang Li; Stephen Cook; Hyon K Choi
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

6.  The stability of metabolic syndrome in children and adolescents.

Authors:  Jennifer K Gustafson; Lisa B Yanoff; Benjamin D Easter; Sheila M Brady; Margaret F Keil; Mary D Roberts; Nancy G Sebring; Joan C Han; Susan Z Yanovski; Van S Hubbard; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

7.  Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study.

Authors:  M G Frontini; S R Srinivasan; G S Berenson
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

8.  Patterns of change in cardiometabolic risk factors associated with the metabolic syndrome among children and adolescents: the Fels Longitudinal Study.

Authors:  Chaoyang Li; Earl S Ford; Terry T-K Huang; Shumei S Sun; Elizabeth Goodman
Journal:  J Pediatr       Date:  2009-09       Impact factor: 4.406

9.  Association of fasting insulin level with serum lipid and lipoprotein levels in children, adolescents, and young adults: the Bogalusa Heart Study.

Authors:  X Jiang; S R Srinivasan; L S Webber; W A Wattigney; G S Berenson
Journal:  Arch Intern Med       Date:  1995-01-23

10.  Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease.

Authors:  M D DeBoer; M J Gurka; J A Morrison; J G Woo
Journal:  Int J Obes (Lond)       Date:  2016-05-02       Impact factor: 5.095

View more
  3 in total

1.  Triglyceride to high-density lipoprotein cholesterol ratio in adolescence as a predictive marker of metabolic syndrome and obesity in early adulthood in China.

Authors:  Fang Zhou; Xiaoshi Sun; Juan Liu; Linlin Li; Ling Li; Ping Li
Journal:  Endocrine       Date:  2022-03-07       Impact factor: 3.633

2.  Derivation and validation of sex-specific continuous metabolic syndrome scores for the Mexican adult population.

Authors:  Eduardo Pérez-Castro; Flaviano Godínez-Jaimes; Martín Uriel Vázquez-Medina; María Esther Ocharan-Hernández; Cruz Vargas-De-León
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

3.  Rest-activity rhythms in emerging adults: implications for cardiometabolic health.

Authors:  Elissa K Hoopes; Melissa A Witman; Michele N D'Agata; Felicia R Berube; Benjamin Brewer; Susan K Malone; Michael A Grandner; Freda Patterson
Journal:  Chronobiol Int       Date:  2021-01-13       Impact factor: 2.877

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.